Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cabaletta Bio, Inc. - Common Stock (NQ:CABA)

2.470 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cabaletta Bio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio Announces Appointment of Steve Gavel as Chief Commercial Officer and Award of Inducement Grant
From Cabaletta Bio
Via GlobeNewswire
Which stocks are moving after the closing bell on Friday?
Discover the top movers in Friday's after-hours session and stay informed about the post-market dynamics. 
Via Chartmill
These stocks are moving in today's session
Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements. 
Via Chartmill
Cabaletta Bio Presents First Rese-cel Data with No Preconditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio to Participate in Upcoming Investor Conferences in September
From Cabaletta Bio
Via GlobeNewswire
Vinay Prasad's Comeback To FDA Sparks Debate Over Regulatory Direction
Vinay Prasad returns as FDA's CBER director after brief exit, raising questions on rare disease drug approvals and mRNA vaccine oversight. 
Via Benzinga
Cabaletta Bio (CABA) Q2 Loss Widens 30%
Via The Motley Fool
Topics Intellectual Property
Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update
From Cabaletta Bio
Via GlobeNewswire
What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?
Vinay Prasad exits FDA's biologics division following pressure over Sarepta's Elevidys approval and regulatory controversies. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
FDA Eases Access To Life-Saving Gene Therapies For Blood Cancers
FDA lifts REMS for approved CAR-T therapies, easing hospital restrictions and signaling broader future access in oncology and autoimmune treatment. 
Via Benzinga
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
Stay up-to-date with the latest market trends one hour before the close of the markets on Wednesday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Top movers analysis in the middle of the day on 2025-06-11: top gainers and losers in today's session.
Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
Which stocks are gapping on Wednesday?
In today's session, there are notable price gaps in the US markets on Wednesday. Take a closer look at the stocks that are gap up and gap down. 
Via Chartmill
Cabaletta Bio Announces Pricing of Public Offering of Securities
From Cabaletta Bio
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Cabaletta Bio Announces Proposed Public Offering of Securities
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference
From Cabaletta Bio
Via GlobeNewswire
Top movers in Friday's pre-market session
As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Cabaletta Bio Stock Surges To 2-Month High On Autoimmune Therapy Progress; Retail’s Pleased
The company announced the addition of two subtype-specific cohorts to its RESET-Myositis trial and received RMAT designation from the FDA for rese-cel. 
Via Stocktwits
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
These stocks are gapping in today's session
Let's delve into the US markets on Thursday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks. 
Via Chartmill
Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts
From Cabaletta Bio
Via GlobeNewswire
Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Cabaletta Bio
Via GlobeNewswire
Cellares and Cabaletta Bio Successfully Complete Manufacturing Technology Adoption Program for Rese-cel Using the Cell Shuttle™ Platform
From Cellares
Via Business Wire
Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference
From Cabaletta Bio
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.